Trial Roundup

Trial Roundup

ASH Clinical News’ Associate Editors select clinical trials to keep an eye on

Measles Virus in Myeloma, SGN-CD33A in AML, and more

LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (NCT02326584) Study Design: Non-randomized, open-label, parallel-assignment safety/efficacy...

APEX, STORM, and more

LEUKEMIA Selected by David Steensma, MD A Study of the Safety and Pharmacokinetics of RO6839921, an MDM2 Antagonist, in Patients with Advanced Cancers, including Acute Myeloid...

Oral ABL001 in CML, poloxamer 188 in vaso-occlusive crisis of SCD, and more

LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute...

ACE-536 for MDS, Vorinostat in SCD, and more

LEUKEMIA Selected by David Steensma, MD A Phase 2, Open-Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1...

ELOQUENT-2, SUSTAIN, and more

LEUKEMIA Selected by David Steensma, MD Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (NCT02267278) Study Design: Open-label, single-group assignment safety/efficacy study Study Start Date: January 2015 ...

ATTRACT, PD-1 Blockade, and more

LEUKEMIA Selected by David Steensma, MD Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (NCT02055781) Study Design: Randomized, open-label, parallel assignment safety/efficacy study Study...

The AG-221 Study, ASPIRE, and More

LEUKEMIA TRIALS Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (NCT01915498)  Study design: Open-label, single-group assignment safety study ...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.